SVB Leerink Maintains Outperform on Cogent Biosciences, Raises Price Target to $15
SVB Leerink analyst Andrew Berens maintains Cogent Biosciences (NASDAQ:COGT) with a Outperform and raises the price target from $14 to $15.
91 Biggest Movers From Friday
Gainers
RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Mid-Afternoon Market Update: Dow Drops Over 600 Points; Fulcrum Therapeutics Shares Tumble
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 600 points on Friday.
Why Shares Of Cogent Biosciences Are Trading Higher
Cogent Biosciences, Inc. (NASDAQ: COGT) shares are trading higher after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Mid-Day Market Update: Nasdaq Dips 400 Points; Cogent Biosciences Shares Jump
U.S. stocks traded lower midway through trading, with the Nasdaq Composite tumbling around 400 points on Friday.
44 Stocks Moving In Friday’s Mid-Day Session
Gainers
Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Mid-Morning Market Update: Markets Open Lower; US Inflation Rate Accelerates to 8.6%
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 600 points on Friday.
UPDATE: Cogent Biosciences Says ‘All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment’
All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment
All bone marrow biopsy-assessed
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.